Rocket Pharmaceuticals, Inc.
RCKT
$4.87
$0.142.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 86.50M | 97.15M | 105.91M | 108.26M | 101.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.52M | 247.18M | 264.18M | 270.22M | 273.21M |
| Operating Income | -228.52M | -247.18M | -264.18M | -270.22M | -273.21M |
| Income Before Tax | -223.12M | -240.91M | -257.30M | -258.03M | -258.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -223.12 | -240.91 | -257.30 | -258.03 | -258.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -223.12M | -240.91M | -257.30M | -258.03M | -258.75M |
| EBIT | -228.52M | -247.18M | -264.18M | -270.22M | -273.21M |
| EBITDA | -217.49M | -236.01M | -253.87M | -260.11M | -263.83M |
| EPS Basic | -2.01 | -2.25 | -2.51 | -2.63 | -2.73 |
| Normalized Basic EPS | -1.28 | -1.43 | -1.59 | -1.69 | -1.76 |
| EPS Diluted | -2.01 | -2.25 | -2.51 | -2.63 | -2.73 |
| Normalized Diluted EPS | -1.28 | -1.43 | -1.59 | -1.69 | -1.76 |
| Average Basic Shares Outstanding | 444.47M | 430.21M | 412.80M | 395.53M | 378.98M |
| Average Diluted Shares Outstanding | 444.47M | 430.21M | 412.80M | 395.53M | 378.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |